(R)-BDP9066 |
| Catalog No.GC63906 |
Le (R)-BDP9066 est un puissant inhibiteur de la kinase de liaison Cdc42 liée À la dystrophie myotonique (MRCK). (R)-BDP9066 bloque l'invasion des cellules cancéreuses. (R)-BDP9066 a le potentiel pour la recherche de maladies prolifératives, telles que le cancer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2284549-25-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(R)-BDP9066 is a potent inhibitor of myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK). (R)-BDP9066 blocks cancer cell invasion. (R)-BDP9066 has the potential for the research of proliferative diseases, such as cancer.
[1]. Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer. Patent WO2019034890A1.
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *